Pharmacological and Nonpharmacological Treatments for Painful Diabetic Peripheral Neuropathy.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or quantitative data synthesis
PubMed 37670573 · doi:10.4093/dmj.2023.0018
What was done
This narrative review summarizes currently available pharmacological and nonpharmacological treatment strategies for painful diabetic peripheral neuropathy (DPN), detailing symptomatic management principles and FDA-approved modalities.
What was found
The abstract reports that the lifetime prevalence of DPN is >50%, with 15% to 25% of individuals with diabetes experiencing neuropathic pain. Because disease-modifying treatments are absent, management emphasizes symptom relief alongside glycemic and risk-factor control. Classes of drugs discussed include gabapentinoids, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, alpha-lipoic acid, sodium channel blockers, and topical capsaicin. FDA-approved options highlighted include pregabalin, duloxetine, tapentadol, the 8% capsaicin patch, and spinal cord stimulation. No comparative efficacy data or numerical trial results are reported.
Why it matters
It outlines clinical management pathways and regulatory-approved options for a common, debilitating complication that significantly compromises patient quality of life through sleep disturbance, anxiety, and depression.
Limits
The abstract describes a narrative review rather than a systematic review or meta-analysis; no search strategy, study selection criteria, sample sizes, or quality assessments are provided. Quantitative comparative efficacy metrics and adverse event rates are omitted.
Cited by
- supports Diabetic neuropathy occurs in more than 50% of diabetics at some point during their lifetime.
- supports Approximately 50% of people with diabetes develop neuropathy.